Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | September 06, 2024 | September 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date September 06, 2024 · Filed September 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,651 |
Reported balance
After 2024-09-06 transaction · row 1
1 source rowRow 1 · 2024-09-06 · Gift · Disposed 230,000 · Balance 35,651 |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2022 GRAT | 0 |
Reported balance
After 2024-09-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-06 · Gift · Disposed 302,179 · Balance 0 F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2024 GRAT | 419,574 |
Reported balance
After 2024-09-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-06 · Gift · Acquired 419,574 · Balance 419,574 F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Ayers Family Trust | 122,605 |
Reported balance
After 2024-09-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-09-06 · Gift · Acquired 112,605 · Balance 122,605 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2021 Filed Feb 22, 2021 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $555.56 | $555,561.30 |
DisclosureSEC source: 0001567619-21-004615 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,737 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,000 | $79.54 | $79,540.00 |
DisclosureSEC source: 0001567619-21-004615 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 22, 2021 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004615 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,737 Read SEC document |
| November 16, 2020 Filed Dec 2, 2020 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 2,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-020565 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,857 Read SEC document |
| November 16, 2020 Filed Dec 11, 2020 22:01 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 2,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-020983 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,737 F1 · balance_after: This amendment is being filed to correct an error in the amount of securities reported as beneficially owned directly by the reporting person. Read SEC document |
| November 06, 2020 Filed Nov 11, 2020 00:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,700 | $471.34 | $801,282.93 |
DisclosureSEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709,991 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $471.16 to a high of $471.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 06, 2020 Filed Nov 11, 2020 00:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,688 | $470.44 | $794,102.21 |
DisclosureSEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 711,691 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $470.12 to a high of $471.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 06, 2020 Filed Nov 11, 2020 00:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,899 | $469.76 | $892,082.03 |
DisclosureSEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,379 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $469.112 to a high of $470.11 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 06, 2020 Filed Nov 11, 2020 00:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 900 | $468.17 | $421,350.75 |
DisclosureSEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715,278 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $467.87 to a high of $468.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 06, 2020 Filed Nov 11, 2020 00:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 283 | $466.86 | $132,120.11 |
DisclosureSEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,178 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $466.732 to a high of $467.165 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $476.73 | $190,692.00 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 23 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,461 Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 200 | $471.17 | $94,234.00 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 22 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,861 Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 25 | $470.99 | $11,774.75 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 21 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,061 Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,165 | $470.36 | $547,964.74 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 20 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,086 F17 · price: Represents the weighted average price of the shares sold ranging from a low of $469.94 to a high of $470.935 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,525 | $468.39 | $714,293.68 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 19 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,251 F16 · price: Represents the weighted average price of the shares sold ranging from a low of $468.12 to a high of $468.763 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,007 | $467.68 | $2,341,665.75 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 18 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,776 F15 · price: Represents the weighted average price of the shares sold ranging from a low of $467.08 to a high of $467.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,259 | $466.16 | $1,053,058.15 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 17 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,783 F14 · price: Represents the weighted average price of the shares sold ranging from a low of $465.79 to a high of $466.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,707 | $465.10 | $1,724,142.01 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 16 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,042 F13 · price: Represents the weighted average price of the shares sold ranging from a low of $464.66 to a high of $465.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 846 | $463.55 | $392,163.30 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,749 F12 · price: Represents the weighted average price of the shares sold ranging from a low of $463.325 to a high of $463.86 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2020 Filed Nov 12, 2020 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 245 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-019311 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,746 Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $489.51 | $146,853.00 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,595 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $480.45 to a high of $480.63 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $479.62 | $191,848.00 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,895 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $479.37 to a high of $479.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 307 | $476.64 | $146,328.51 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,295 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $476.36 to a high of $477.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,900 | $475.73 | $903,891.94 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,602 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $475.24 to a high of $476.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 207 | $474.59 | $98,241.06 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,502 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $474.10 to a high of $475.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,172 | $473.40 | $554,825.85 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,709 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $473.00 to a high of $473.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,500 | $472.52 | $708,775.95 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,881 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $472.00 to a high of $472.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $471.20 | $141,360.00 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,381 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $470.94 to a high of $471.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 900 | $470.09 | $423,078.93 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,681 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $469.85 to a high of $470.61 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,068 | $469.12 | $1,439,268.14 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,581 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $468.62 to a high of $469.42 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 800 | $467.97 | $374,376.00 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,649 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $467.52 to a high of $478.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1 | $465.79 | $465.79 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,449 Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 85 | $461.80 | $39,253.00 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,450 Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $459.99 | $229,995.00 |
DisclosureSEC source: 0001567619-20-018870 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,535 Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $446.98 | $134,094.00 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 18 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,035 F15 · price: Represents the weighted average price of the shares sold ranging from a low of $446.74 to a high of $447.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 908 | $446.02 | $404,982.44 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 17 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,335 F14 · price: Represents the weighted average price of the shares sold ranging from a low of $445.46 to a high of $446.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,011 | $444.69 | $1,338,974.24 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 16 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,243 F13 · price: Represents the weighted average price of the shares sold ranging from a low of $444.35 to a high of $445.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,622 | $443.84 | $1,607,596.09 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747,254 F12 · price: Represents the weighted average price of the shares sold ranging from a low of $443.17 to a high of $444.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,357 | $442.14 | $599,980.86 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,876 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $441.89 to a high of $442.77 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $440.09 | $176,036.00 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,233 Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 700 | $439.56 | $307,690.74 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,633 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $439.029 to a high of $439.77 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 134 | $437.32 | $58,600.88 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,333 Read SEC document |
| November 03, 2020 Filed Nov 12, 2020 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-019311 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,991 Read SEC document |
| November 03, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $446.98 | $134,094.00 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 19 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,915 F16 · price: Represents the weighted average price of the shares sold ranging from a low of $446.74 to a high of $447.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 908 | $446.02 | $404,982.44 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 18 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,215 F15 · price: Represents the weighted average price of the shares sold ranging from a low of $445.46 to a high of $446.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,011 | $444.69 | $1,338,974.24 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 17 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,123 F14 · price: Represents the weighted average price of the shares sold ranging from a low of $444.35 to a high of $445.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,622 | $443.84 | $1,607,596.09 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 16 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 721,134 F13 · price: Represents the weighted average price of the shares sold ranging from a low of $443.17 to a high of $444.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,357 | $442.14 | $599,980.86 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,756 F12 · price: Represents the weighted average price of the shares sold ranging from a low of $441.89 to a high of $442.77 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 03, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $440.09 | $176,036.00 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,113 Read SEC document |
| November 03, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 700 | $439.56 | $307,690.74 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,513 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $439.029 to a high of $439.77 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.